Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01833143
First received: April 11, 2013
Last updated: August 13, 2014
Last verified: August 2014

April 11, 2013
August 13, 2014
April 2013
April 2015   (final data collection date for primary outcome measure)
efficacy of single-agent subcutaneous bortezomib [ Time Frame: 2 years ] [ Designated as safety issue: No ]
The following evaluations will be conducted to assess the efficacy of bortezomib - radiographic response rate by RECIST v1.1
efficacy of single-agent subcutaneous bortezomib [ Time Frame: 2 years ] [ Designated as safety issue: No ]
The following evaluations will be conducted to assess the efficacy of bortezomib - radiographic response rate by RECIST v1.1, progression-free survival, and overall survival.
Complete list of historical versions of study NCT01833143 on ClinicalTrials.gov Archive Site
  • Efficacy [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Secondary endpoints of progression free survival, 8-week stable disease, and overall survival will be evaluated according to RECIST v.1.1 criteria as well.
  • Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Before each drug dose, the patient will be evaluated for possible toxicities that may have occurred after the previous dose(s). Toxicities are to be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v4.0,).
  • response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Secondary endpoints of progression free survival, 8-week stable disease, and overall survival will be evaluated according to RECIST v.1.1 criteria as well.
  • Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Before each drug dose, the patient will be evaluated for possible toxicities that may have occurred after the previous dose(s). Toxicities are to be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v4.0,.
Not Provided
Not Provided
 
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation associated with their lung cancer.

Not Provided
Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-Small Cell Lung Cancer
  • Drug: Bortezomib
  • Drug: Acyclovir
Experimental: Bortezomib
Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
Interventions:
  • Drug: Bortezomib
  • Drug: Acyclovir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
25
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologic or cytologic evidence of non-small cell lung cancer (NSCLC)
  • Documented KRAS mutation
  • History of smoking < 100 cigarettes (never-smoker) OR patient with a KRAS G12D mutation regardless of smoking history
  • Clinical stage IIIB/IV or recurrent/medically inoperable NSCLC
  • Age ≥ 18 years
  • Three (3) weeks since last chemotherapy, and three (3) weeks since prior radiation therapy and recovered from treatment
  • Karnofsky performance status ≥ 70%
  • Adequate hematologic, and/or hepatic function WBC ≥ 3,000/ul or absolute neutrophil count ≥ 1,000/ul Hemoglobin ≥ 9.0 g/dl Platelet count ≥ 100,000/ul AST ≤ 2.0 X ULN (upper limit of normal)
  • Total bilirubin ≤1.5 x ULN Measurable indicator lesions by RECIST v1.1 criteria.
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse.
  • Male subjects must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.

Exclusion Criteria:

  • Uncontrolled central nervous system metastases defined as any lesion which is either a. symptomatic, or requiring escalating doses of corticosteroids
  • Significant medical history or unstable medical condition such as uncontrolled diabetes myocardial infarction within 6 months prior to enrollment New York Heart Association Class III or IV heart failure severe uncontrolled ventricular arrythmias uncontrolled angina ECG evidence of acute ischemia or active conduction system abnormalities
  • Baseline ≥ grade 2 peripheral neuropathy by CTCAE v 4.0 (Appendix B)
  • Known hypersensitivity to boron or mannitol
  • Female patients who are pregnant/lactating or have a positive serum or urine β-hCG pregnancy test
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • No active concurrent malignancy, with the exception of in-situ malignancy completely resected basal cell carcinoma or squamous cell carcinomas of the skin low-risk prostate cancer after curative therapy
  • Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Both
18 Years and older
No
Contact: Gregory Riely, MD PhD 646-888-4199
Contact: Paul Paik, MD 646-888-4202
United States
 
NCT01833143
12-222
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Millennium Pharmaceuticals, Inc.
Principal Investigator: Gregory Riely, MD, PhD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP